 "Dr Reddy's Labs")
Dr Reddy's Laboratories Limited announced on Wednesday that its US subsidiary Promius Pharma LLC launched Sernivo (betamethasone dipropionate) spray, 0.5% in the US.
Servino Spray, a prescription topical steroid approved by the US Food and Drug Administration (USFDA) in February, 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age of older.
Raghav Chari, executive vice-president, Proprietary Products Group at Dr Reddy's Laboratories said: "We are proud to bring Sernivo Spray to patients across the US. As, it is an another significant milestone for Promius Pharma because we are the emerging leader in the dermatology space and, committed to developing innovative treatment options."
Promius has conducted two multi-center, randomised, double-blind, vehicle-controlled clinical trials in subjects aged 18 years and older with moderate plaque psoriasis to evaluate the safety and efficacy of Sernivo Spray.Treatment success was achieved in significantly more subjects using Sernivo Spray than vehicle at both Day 15 and Day 29 across both studies, according to the company.
